Clinical Trial Detail

NCT ID NCT02715011
Title Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

acute myeloid leukemia

Therapies

JNJ-63709178

Age Groups: senior adult

No variant requirements are available.